BusinessNewsAPI
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Overview
Genevant Sciences and Arbutus Biopharma announced a $2.25 billion global settlement with Moderna that resolves major patent litigation and could include a further contingent payment, underscoring large financial stakes in biotech legal disputes. Moderna’s recent 14% stock surge on news of its hantavirus vaccine work shows how clinical progress can rapidly influence investor sentiment and may help offset concerns about settlement costs. The case illustrates how legal and scientific developments together can materially change company valuations and industry dynamics.
Entities
ORGGenevant SciencesORGArbutus BiopharmaORGModerna
Relationship Graph
Click a connection line between nodes to view confidence and evidence.
Nodes: 3 · Connections: 2
Caused by
Led to
Related to
Same event
Press enter or space to select a node. You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.
Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.
Click a connection for evidence · click a node to open it
Select a connection to see why these events are linked.